Results 191 to 200 of about 24,454,690 (224)
Some of the next articles are maybe not open access.
Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis
Current Medicinal Chemistry, 2020Background: Angiopoietin-Like Proteins (ANGPTLs) are structurally related to the angiopoietins. A total of eight ANGPTLs (from ANGPTL1 to ANGPTL8) have been identified so far. Most ANGPTLs possess multibiological functions on lipid metabolism, atherosclerosis, and cancer.
openaire +2 more sources
Genetics and regulation of angiopoietin-like proteins 3 and 4
Current Opinion in Lipidology, 2006Lipoprotein lipase activity in a given tissue is the rate limiting step for the uptake of triglyceride-derived fatty acids. Imbalances in the partitioning of fatty acids have major metabolic consequences. Given the central role of lipoprotein lipase in energy metabolism, the discovery of new molecules that affect the activity of lipoprotein lipase ...
openaire +2 more sources
Evaluation of angiopoietin-like protein 3 (ANGPTL3) levels in polycystic ovary syndrome
Life Sciences, 2020Angiopoietin-like protein 3 (ANGPTL3) is recognized as a regulator of lipid metabolism. However, little is known about its association with insulin resistance in polycystic ovary syndrome (PCOS) setting. The present study aimed to investigate the serum levels of ANGPTL3 and adiponectin in PCOS women compared to healthy controls.In this study, a total ...
Akram, Vatannejad +7 more
openaire +2 more sources
Antibodies to human angiopoietin-like protein 3: a patent evaluation of WO2012174178
Expert Opinion on Therapeutic Patents, 2013The patent WO2012174178 claims the effect of a fully human antibody or antigen-binding fragment of a human antibody which specifically binds and neutralizes, inhibits, blocks, abrogates, reduces or interferes with the activity of human angiopoietin-like protein 3 (hANGPTL3).
Katsuyuki, Nakajima, Junji, Kobayashi
openaire +2 more sources
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia
Current Atherosclerosis Reports, 2023The role of the inhibition of ANGPTL3 in severe or refractory hypercholesterolemia is well documented, less in severe hyperTG. This review focuses on the preclinical and clinical development of ApoC-III inhibitors and ANGPTL3, 4, and 3/8 complex inhibitors for the treatment of severe or refractory forms of hypertriglyceridemia to prevent cardiovascular
Miriam, Larouche +3 more
openaire +2 more sources
Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia
Current Opinion in Endocrinology, Diabetes & ObesityPurpose of review To summarize recent advances in therapeutic strategies targeting angiopoietin-like protein 3 (ANGPTL3), a central regulator of triglyceride and remnant lipoprotein metabolism, and to discuss the potential of emerging pharmacologic approaches
Pablo, Corral +2 more
openaire +2 more sources
Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment
Cardiology in Review, 2019Angiopoietin-like 3 protein (ANGPTL3) is an inhibitor of both lipoprotein lipase and endothelial lipase in humans. Population studies indicate a relationship between loss of function mutations in ANGPTL3 and favorable reductions in triglycerides and non- high-density lipoprotein cholesterol.
William, Lang, William H, Frishman
openaire +2 more sources
Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes
Biochemical and Biophysical Research Communications, 2003Our previous work identified a genetic mutation in the gene encoding angiopoietin-like protein 3 (Angptl3) in KK/Snk mice (previously KK/San), a mutant strain of KK obese mice. KK/Snk had significantly lower plasma triglyceride and free fatty acid (FFA) than KK mice. Human ANGPTL3 treatment increased both plasma triglyceride and FFA.
Mitsuru, Shimamura +8 more
openaire +2 more sources
Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent
Current Opinion in LipidologyPurpose of review Triglyceride-rich lipoproteins (TRLs) and LDL remain major drivers of atherosclerotic cardiovascular disease, and angiopoietin-like protein 3 (ANGPTL3) has emerged as a promising target to lower both triglycerides and LDL cholesterol (LDL-C).
Nicholas A, Marston, André, Zimerman
openaire +2 more sources
Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia
Atherosclerosis, 2009Angiopoietin-like protein 3, a liver-derived plasma protein, increases plasma triglycerides (TG) in mice by suppressing the activity of lipoprotein lipase, a key enzyme in plasma TG clearance. Uremic dyslipidemia is characterized by increased TG-rich lipoproteins such as very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL ...
Tetsuo, Shoji +9 more
openaire +2 more sources